ArticleCureus2025
Early Clinical Outcomes of Definitive Volumetric Modulated Arc Therapy in Locally Advanced Oral Cavity Cancers: A Prospective, Single-Center Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Evidence from prospective evaluations of outcomes in locally advanced, surgically unresectable oral cavity squamous cell carcinoma (OCSCC) treated with definitive chemoradiotherapy is limited. Methodology We conducted a single-center, prospective, observational study to evaluate early tumor response, acute toxicities, treatment compliance, and survival outcomes in patients with unresectable, locally advanced OCSCC treated with volumetric modulated arc therapy (VMAT) with concurrent three-weekly cisplatin in feasible patients. Results A total of 55 consecutive patients (median age = 56 years; Eastern Cooperative Oncology Group performance status = 0-2) were included. Overall, 40 (72.7%) patients received concurrent cisplatin-based chemoradiotherapy, and 15 (27.3%) underwent VMAT alone. At three months post-treatment, the objective response rate for the entire cohort was 78.2% (95% confidence interval (CI) = 65.0-88.2%), and the disease control rate was 90.9% (95% CI = 80.0-97.0%). Severe (grade ≥3) mucositis occurred in approximately half of the patients, whereas other acute and hematologic toxicities were generally ≤25%. The median overall treatment time was 43 days. With a median follow-up of 13.4 months, the median progression-free survival (PFS) and overall survival (OS) were 16.7 (95% CI = 14.9-18.5), and 18.6 months (95% CI = 16.0-21.2), respectively, with one-year PFS and OS rates of 78% (95% CI = 67-89) and 80% (95% CI = 69-91), respectively. Conclusions In patients with unresectable, locally advanced OCSCC with good performance status, definitive chemoradiotherapy delivered with VMAT is feasible and effective, achieving reasonable response rates and acceptable acute toxicities; however, longer follow-up is required to fully assess late toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.